Author

F. Caccuri

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 2 Organism:human· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Caruso· 3 shared A. Corbelli· 1 shared A. De Luigi· 1 shared A. Piotti· 1 shared A. R. Beccari· 1 shared A. Zani· 1 shared C. Chen· 1 shared C. Fracasso· 1 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

A. Caruso

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants by Modular, Tetravalent, Bi-paratopic Antibodies

S. Miersch, R. Saberianfar, C. Chen, N. Sharma, G. K. Amarasinghe, F. Caccuri, A. Zani, A. Caruso, G. Novelli, S. S. Sidhu

This study develops a tetravalent antibody format that neutralizes SARS-CoV-2 variants with high potency and breadth, surpassing conventional bivalent antibodies.

bioRxiv · Nov 2, 2021Bioengineering

Characterization of raloxifene as potential pharmacological agent against SARS-CoV-2 and its variants

D. Iaconis, C. Talarico, C. Manelfi, M. C. Cesta, M. Zippoli, F. Caccuri, G. Matusali, L. Bordi, L. Scorzolini, E. M. Bucci, A. Caruso, E. Nicastri, M. Allegretti, A. R. Beccari

This paper identifies raloxifene as a potential drug candidate for treating COVID-19 through virtual screening and pharmacological characterization across multiple viral variants.

bioRxiv · Oct 22, 2021Pharmacology & Toxicology

Doxycycline inhibition of a pseudotyped virus transduction does not translate to inhibition of SARS-CoV-2 infectivity

L. Diomede, S. Baroni, A. De Luigi, A. Piotti, J. Lucchetti, C. Fracasso, L. Russo, V. Bonaldo, N. Panini, F. Filippini, F. Fiordaliso, A. Corbelli, M. Beeg, M. Pizzato, F. Caccuri, , M. Salmona

This paper tests doxycycline's effect on SARS-CoV-2 infection using pseudovirus and clinical strains, finding it inhibits pseudovirus transduction but not actual SARS-CoV-2 entry and replication.

bioRxiv · Jul 30, 2021Pharmacology & Toxicology